title: [Development of cell-selective targeting systems of NFkappaB decoy for inflammation therapy].
abstract: NFkappaB regulate several inflammatory related molecules and evoke immune and inflammatory response by several stimuli, therefore inhibition of NFkappaB activation would be a novel therapeutic strategy. To date, there are many conventional drugs including nonsteroldal or steroldal anti-inflammatory drugs or immune suppressors etc. were known to inhibit NFkappaB activation, however, several side effects were also reported. Recently, double stranded oligonucleotide including NFkappaB binding sequence, called NFkappaB decoy, was developed to prevent NFkappaB activation, which is powerful tool in a new class of anti-gene strategy for molecular therapy with low side effect. However, NFkappaB decoy is easily degraded by nuclease and rapidly excreted to urine, therefore it is necessary to develop carrier for NFkappaB decoy therapy. Here, we shall review delivery system for NFkappaB decoy and introduce our cell-selective delivery system for NFkappaB decoy using sugar decorated cationic liposomes.
authors.affiliation: Graduate School of Pharmaceutical Sciences, Kyoto University, Japan.
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kawakami
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Hashida
mesh_terms: D000818:Animals; D004247:DNA; D016503:Drug Delivery Systems; D018390:Gene Targeting; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000628:therapy*; D008081:Liposomes; D008358:Mannose; D016328:NF-kappa B / Q000235:genetics / Q000502:physiology*; D009841:Oligonucleotides / Q000008:administration & dosage*
chemical_list: D008081:Liposomes; D016328:NF-kappa B; D009841:Oligonucleotides; D004247:DNA; D008358:Mannose